Bretylium Tosylate
Bretylium tosylate initially releases norepinephrine stores from adrenergic nerve terminals but subsequently prevents further norepinephrine release. This initial catecholamine release may aggravate some arrhythmias and produce transient hypertension. Although the chemical sympathec-tomy-like state may be antiarrhythmic, other electrophysiological properties may also contribute to the antiarrhythmic properties of bretylium. Bretylium does not depress myocardial contractility or affect vagal reflexes. After the initial increase in blood pressure, the drug may subsequently cause hypotension, usually orthostatic and controlled if the patient is supine. Bretylium is poorly absorbed orally and is commonly administered intravenously. Bretylium has been reported to induce spontaneous termination of ventricular fibrillation. Bretylium is indicated in patients with life-threatening ventricular arrhythmias that have not responded to lidocaine and possibly to other drugs.
- Aminoaciduria
- CHROMIC PANCREATITIS
- PERIPHERAL ANEURYSMS AMD FISTULAE
- Hepatic Encephalopathy
- Blood Chemistries
- CYSTIC FIBROSIS
- OBLITERATIVE OR OBSTRUCTIVE PULMONARY HYPERTENSION
- POSTCAPILLARY PULMONARY HYPERTENSION
- CLINICAL MANIFESTATIONS OF MALABSORPTION
- DC CARDIOVERSION AND DEFIBRILLATION
- SCREENING TESTS OF HEPATOBILIARY DISEASE
- Endocrine Systems
- CONTROL OF BREATHING IN DISEASE STATES
- CHARACTERISTICS OF ABDOMINAL PAIN
- PERICARDIAL EFFUSIOH
- PROSTHETIC VALVES
- Alberto N. v. Hawkins
- Hematopoietic System
- EMBOLIC DISEASE
- OTHER THERAPEUTIC MODALITIES
- Other Cystic Diseases
- HHSC Legislative Appropriations Request (LAR)
- PATHOPHYSIOLOGY OF AIRWAY OBSTRUCTION
- SPECIFIC PATHOGENIC ORGANISMS
- Urinary Tract Infection
- NONMEDICAL MANAGEMENT OF ANGINA PECTORIS
- Endocrine and Other Considerations
- MEDIASTINAL DISEASE
- PHYSICAL EXAMINATION
- DRUGS
- TESTS OF HEPATIC FUNCTION
- Incidence
- NORMAL INTESTINAL PHYSIOLOGY
- VENTILATION
- PNEUMOTHORAX